{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:40:48Z","timestamp":1760190048853,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The lack of antibiotics with a novel mode of action associated with the spread of drug resistant bacteria make the fight against infectious diseases particularly challenging. A quinoline core is found in several anti-infectious drugs, such as mefloquine and bedaquiline. Two main objectives were set in this work. Firstly, we evaluated the anti-mycobacterial properties of the previous quinolines 3, which have been identified as good candidates against ESKAPEE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. and Escherichia coli) bacteria. Secondly, a new series 4 was designed and assessed against the same bacteria strains, taking the pair of enantiomers 3m\/3n as the lead. More than twenty compounds 4 were prepared through a five-step asymmetric synthesis with good enantiomeric excesses (&gt;90%). Interestingly, all compounds of series 3 were efficient on M. avium with MIC = 2\u201316 \u00b5g\/mL, while series 4 was less active. Both series 3 and 4 were generally more active than mefloquine against the ESKAPEE bacteria. The quinolines 4 were either active against Gram-positive bacteria (MIC \u2264 4 \u00b5g\/mL for 4c\u20134h and 4k\/4l) or E. coli (MIC = 32\u201364 \u00b5g\/mL for 4q\u20134v) according to the global lipophilicity of these compounds.<\/jats:p>","DOI":"10.3390\/ph12020091","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T10:43:32Z","timestamp":1560941012000},"page":"91","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Synthesis and Study of New Quinolineaminoethanols as Anti-Bacterial Drugs"],"prefix":"10.3390","volume":"12","author":[{"given":"Pierre","family":"Laumaill\u00e9","sequence":"first","affiliation":[{"name":"AGIR, EA 4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Dassonville-Klimpt","sequence":"additional","affiliation":[{"name":"AGIR, EA 4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Peltier","sequence":"additional","affiliation":[{"name":"AGIR, EA 4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France"},{"name":"Department of Bacteriology, Amiens University Hospital, 80054 Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-9666","authenticated-orcid":false,"given":"Catherine","family":"Mulli\u00e9","sequence":"additional","affiliation":[{"name":"AGIR, EA 4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Andr\u00e9jak","sequence":"additional","affiliation":[{"name":"AGIR, EA 4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France"},{"name":"Respiratory and Intensive Care Unit, University Hospital Amiens, 80054 Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Da-Nascimento","sequence":"additional","affiliation":[{"name":"AGIR, EA 4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-3148","authenticated-orcid":false,"given":"Sandrine","family":"Castelain","sequence":"additional","affiliation":[{"name":"AGIR, EA 4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France"},{"name":"Department of Bacteriology, Amiens University Hospital, 80054 Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0118-9151","authenticated-orcid":false,"given":"Pascal","family":"Sonnet","sequence":"additional","affiliation":[{"name":"AGIR, EA 4294, UFR of Pharmacy, Jules Verne University of Picardie, 80037 Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"unstructured":"World Health Organization (2016). The Burden of Health Care-Associated Infection Worldwide, World Health Organization.","key":"ref_1"},{"unstructured":"World Health Organization (2018). Global Tuberculosis Report 2018, World Health Organization.","key":"ref_2"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1093\/clinids\/24.Supplement_1.S121","article-title":"Drug-Resistant Tuberculosis: Review of the Worldwide Situation and the WHO\/IUATLD Global Surveillance Project","volume":"24","author":"Cohn","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijid.2016.03.006","article-title":"Update on pulmonary disease due to non-tuberculous mycobacteria","volume":"45","author":"Stout","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2229-516X.112228","article-title":"Bedaquiline: First FDA-approved tuberculosis drug in 40 years","volume":"3","author":"Mahajan","year":"2013","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.biopha.2014.10.007","article-title":"Quinoline: A promising antitubercular target","volume":"68","author":"Keri","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1128\/AAC.44.4.848-852.2000","article-title":"Antimicrobial activities of mefloquine and a series of related compounds","volume":"44","author":"Kunin","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"unstructured":"World Health Organization (2015). Guidelines for the Treatment of Malaria, World Health Organization.","key":"ref_10"},{"doi-asserted-by":"crossref","unstructured":"Fu, H.-G., Li, Z.-W., Hu, X.-X., Si, S.-Y., You, X.-F., Tang, S., Wang, Y.-X., and Song, D.-Q. (2019). Synthesis and biological evaluation of quinoline derivatives as a novel class of broad-spectrum antibacterial agents. Molecules, 24.","key":"ref_11","DOI":"10.3390\/molecules24030548"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.bmc.2018.05.031","article-title":"Facilely accessible quinoline derivatives as potent antibacterial agents","volume":"26","author":"Teng","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00044-016-1732-6","article-title":"Synthesis and antimicrobial activity of novel quinoline derivatives bearing pyrazoline and pyridine analogues","volume":"26","author":"Desai","year":"2016","journal-title":"Med. Chem. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e01798-16","DOI":"10.1128\/AAC.01798-16","article-title":"In Vitro susceptibility testing of Bedaquiline against Mycobacterium avium Complex","volume":"61","author":"Philley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2125.1992.tb04081.x","article-title":"In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum","volume":"33","author":"Basco","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00320-12","article-title":"Identification of (+)-Erythro-Mefloquine as an Active Enantiomer with Greater Efficacy than Mefloquine against Mycobacterium avium Infection in Mice","volume":"56","author":"Bermudez","year":"2012","journal-title":"Antimicrob. Agents Chemother"},{"key":"ref_17","first-page":"1","article-title":"Mefloquine and its enantiomers are active against Mycobacterium tuberculosis in vitro and in macrophages","volume":"2014","author":"Bermudez","year":"2014","journal-title":"Tuberc. Res. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1500106","DOI":"10.1126\/sciadv.1500106","article-title":"Structure of the mycobacterial ATP synthase F1F0 rotor ring in complex with the anti-TB drug bedaquiline","volume":"1","author":"Preiss","year":"2015","journal-title":"Sci. Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/prot.21376","article-title":"A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910","volume":"67","author":"Koymans","year":"2007","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17031","DOI":"10.1038\/nmicrobiol.2017.31","article-title":"Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis","volume":"2","author":"Wong","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.46.6.1680-1687.2002","article-title":"Mefloquine and new related compounds target the F0 Complex of the F0F1 H+-ATPase of Streptococcus pneumoniae","volume":"46","author":"Gorgojo","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1475-2875-11-65","article-title":"Differences in anti-malarial activity of 4-aminoalcohol quinoline enantiomers and investigation of the presumed underlying mechanism of action","volume":"11","author":"Jonet","year":"2012","journal-title":"Malaria J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/cplu.201300074","article-title":"Absolute configuration and antimalarial activity of erythro-mefloquine enantiomers","volume":"78","author":"Agnamey","year":"2013","journal-title":"ChemPlusChem"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/ja.2013.71","article-title":"Side chain length is more important than stereochemistry in the antibacterial activity of enantiomerically pure 4-aminoalcohol quinoline derivatives","volume":"66","author":"Jonet","year":"2013","journal-title":"J. Antibiot."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1021\/jm00290a004","article-title":"Interdependence between physical parameters and selection of substituent groups for correlation studies","volume":"14","author":"Craig","year":"1971","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tetasy.2011.01.003","article-title":"First enantioselective synthesis of 4-aminoalcohol quinoline derivatives through a regioselective SN2 epoxide opening mechanism","volume":"22","author":"Jonet","year":"2011","journal-title":"Tetrahedron: Asymmetry"},{"unstructured":"Clinical and Laboratory Standards Institute (2015). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard, Clinical and Laboratory Standards Institute.","key":"ref_27"},{"unstructured":"Clinical and Laboratory Standards Institute (2011). Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard, Clinical and Laboratory Standards Institute.","key":"ref_28"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1021\/cr60165a003","article-title":"A Re\u00ebxamination of the Hammett Equation","volume":"53","author":"Jaffe","year":"1953","journal-title":"Chem. Rev."},{"unstructured":"Hammett, L.P. (1940). Physical Organic Chemistry, McGraw-Hill Book Company, Inc.","key":"ref_30"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1021\/ja01077a028","article-title":"A new substituent constant, \u03c0, derived from partition coefficients","volume":"86","author":"Fujita","year":"1964","journal-title":"J. Am. Chem. Soc."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/12\/2\/91\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:59:27Z","timestamp":1760187567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/12\/2\/91"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["ph12020091"],"URL":"https:\/\/doi.org\/10.3390\/ph12020091","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2019,6,18]]}}}